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Abstract: Dietary supplementation with sugar cane derivates may modulate low-density lipoprotein
cholesterol (LDL-C) and proprotein convertase subtilisin/kexin type 9 (PCSK9) levels. The purpose
of this study was to determine if dietary supplement (DS), containing Octacosanol (20 mg) and
vitamin K2 (45 µg), could restore the disrupted physiologic relation between LDL-C and serum
PCSK9. Double-blind, randomized, placebo-controlled, single-center study including 87 patients on
chronic atorvastatin therapy was conducted. Eighty-seven patients were randomized to receive DS
(n = 42) or placebo (n = 45), and followed for 13 weeks. Serum PCSK9 levels, lipid parameters and
their relationship were the main efficacy endpoints. The absolute levels of PCSK9 and LDL-C were
not significantly different from baseline to 13 weeks. However, physiologic correlation between %
change of PCSK9 and % change of LDL-C levels was normalized only in the group of patients treated
with DS (r = 0.409, p = 0.012). This study shows that DS can restore statin disrupted physiologic
positive correlation between PCSK9 and LDL-C. Elevated PCSK9 level is an independent risk factor
so controlling its rise by statins may be important in prevention of cardiovascular events.
Keywords: supplementation; Octacosanol; LDL-C; PCSK9; statins
1. Introduction
Data on the lipid-lowering effects of policosanol (alone or in combination with statins)
is contradictory [1], but high-quality studies have disputed any favorable effects on serum
low-density lipoprotein cholesterol (LDL-C) levels [2–6]. It is not clear if genetic differ-
ences are responsible for such a diversity of results, but the use of policosanol has been
discouraged in the current European guidelines for the management of dyslipidemias [7].
Nonetheless, it is widely available as a dietary supplement (alone or in combination with
different nutraceuticals) all over the world.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) and PCSK9 inhibitors have
gained a lot of attention in the last decade. PCSK9 is a protease that promotes lysosomal
degradation of LDL receptor (LDLr), thus regulating the amount of LDL-C in circulation [8].
This mechanism of action of circulating PCSK9 has initiated the development of a novel
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generation of drugs (PCSK9-inhibitors), which effectively block the PCSK9-LDLr interac-
tion and lower LDL-C levels up to 70% [9]. In addition, investigation of the statins-PCSK9
interactions revealed an increase in serum PCSK9 levels as a result of statin therapy, which
could explain reduced full lipid-lowering effects of statins [10,11]. Interestingly, it has
been suggested that policosanol may prevent the rise of PCSK9 levels in patients who start
statin therapy, as well as decrease them in healthy volunteers [12]. Also, several nutraceuti-
cals may decrease PCSK9 levels in animals and humans [13,14]. Nutraceuticals, such as
berberin and curcumin, may inhibit PCSK9 expression through SREBP (sterol-responsive
element binding protein)-independent pathways [15–17]. In contrast, statins increase the
expression of PCSK9 through the activation of SREBP-2, which may attenuate their ben-
eficial effects [18,19]. However, it is not clear if elevated PCSK9 levels (irrespective of
LDL-C values) represent an independent risk factor for future cardiovascular events [20,21]
or not [22,23]. It would be the issue even with the new very recently approved drug
Inclisiran (slow interfering RNA, siRNA) which inhibits PCSK9 synthesis because it has
been administered on top of background statin therapy [24].
Therefore, we investigated in a prospective, single-center, randomized, double-blind,
placebo-controlled trial if a dietary supplement, which contains Octacosanol (20 mg) and
vitamin K2-MK7 (45 µg) may influence the level of PCSK9 and its relationship with LDL-C
in patients on chronic statin therapy.
2. Materials and Methods
2.1. Study Population
One-hundred and seventy-seven outpatients from the Department of Cardiology,
University Clinical Centre Zvezdara, Belgrade, Serbia were initially screened for eligibility.
Finally, 87 patients were examined and subjected to blood analyses to determine lipid
profile parameters and complete biochemistry.
The inclusion criteria were: Both sexes, between the ages of 40–80 years, confirmed
history/diagnosis of hypercholesterolemia or mixed dyslipidaemia, body mass index (BMI)
between 18 and 35 kg/m2, and the use of atorvastatin (20 mg/day) for a minimum of
4 months prior to study entry. The exclusion criteria included serum triglycerides (TG)
levels above 5.6 mmol/L, acute coronary syndrome within the previous month, serious
heart failure, cerebral vascular disease, history of severe infections, known hypersensitivity
to any of the ingredients of the formulation, current use of agents with a potential to interact
with Octacosanol (e.g., high-dose aspirin), recent or chronic use of oral anticoagulant
drugs and anticipated compliance problems. Significant pre-existing diseases including
cancer, liver and/or renal insufficiency, psychiatric disorders, systematic inflammatory
or autoimmune disease were also the exclusion criteria. In addition, patients with serum
alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) levels 3 times
above the upper limit of the normal laboratory range, and/or creatine phosphokinase (CK)
5 times above the upper limit of normal were not included [25].
2.2. Study Design and Protocol
From November 2015 to June 2016 in randomized, double-blind, placebo-controlled
trial, subjects were assigned to receive one capsule daily of dietary supplement or placebo.
The investigated supplement and placebo were produced and provided by AbelaPharm
(Belgrade, Serbia). Dietary supplement contains Octacosanol (20 mg) and vitamin K2-
MK7 (45 µg) (Arteroprotect®; Gnosis S.p.A, Italy). The placebo capsules were identical in
appearance (color, shape, texture) and taste to the supplement but consisted of magnesium
stearate, microcrystalline cellulose and colloidal silicon dioxide. The applied dose of 20 mg
of Octacosanol corresponds to approximately 30 mg of Policosanol. There is no report on
the use of higher Octacosanol doses alone, but previous study used 80 mg of Policosanol
which would correspond to 50 mg of Octacosanol [3].
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Patients were allocated by a computer-generated random sequence of numbers run
by the investigator with no involvement in the study. Only the safety monitor (DK), who
was otherwise uninvolved in the study, could unblind the data.
Subjects were instructed to avoid the use of vitamin K and dietary supplements that
can interfere with serum LDL-C (specifically sterol and stanol products, psyllium-based
fiber supplements, or red yeast rice) or TG levels (fish oil, omega-3 fatty acids), 1 month
prior to the start of the study and during the study.
The recommended low-fat diet and other medications were monitored by a 3-day
food/medication record kept at the baseline and at the end of the study. The patients
were examined and subjected to blood analysis at the baseline, and after 8 and 13 weeks.
During these visits, as well as on the 5th and 10th week, patients were interviewed about
adverse effects. Instructions for use were reconfirmed each week by the same investigator.
Acceptable patient compliance was defined as an overall dietary supplement /placebo
intake of at least 85% of scheduled capsules, which was verified by the number of returned
capsules at the end of 8th and 13th week.
The study was approved by the Zvezdara University Medical Center Office for Human
Research Protections (ethics code number 27102015; date 27 October 2015). The study was
conducted according to the Declaration of Helsinki. All patients gave their written consent
after being informed about the purpose, demands, and possible risks associated with
the study. The trial was registered at Australian New Zealand Clinical Trials Registry as
ACTRN12619000102178; http://www.anzctr.org.au (accessed on 19 January 2021).
2.3. Outcomes
Serum PCSK9 concentrations were measured in duplicate using a commercial, high-
sensitivity, quantitative sandwich enzyme immunoassay Quantikine® (R&D System, Min-
neapolis, MN, USA). This assay recognizes free and LDL receptor bound PCSK9. The intra-
and inter-assay coefficients of variation vary from 4.1% to 6.5%, and the range for serum
values in a random sample of healthy individuals was 177–460 ng/mL, with a mean ± S.D.
value of 313 ± 71 ng/mL. The mean threshold for detection was 0.096 ng/mL.
Additionally, we evaluated the concentrations of lipid parameters including total
cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), LDL-C, TG, apolipoprotein
A1 (ApoA1), and apolipoprotein B100 (ApoB100), as well as AST, ALT, CK, C-reactive
protein (CRP), and glucose. All biochemical parameters were measured using an automated
biochemistry analyzer (Hitachi 7150, Tokyo, Japan) employing commercial kits (Boehringer,
Mannheim, Germany).
Blood sample collection was performed between 9:00 and 10:00 a.m., after at least 8 h
of overnight fasting.
2.4. Safety Evaluation
Physical and clinical examinations, vital signs (pulse rate, diastolic and systolic blood
pressure) and laboratory indicators (ALT, AST, fasting glucose, and CK) were evaluated
for safety assessment. At each visit any unusual adverse effects was reported by using
appropriate record forms.
2.5. Statistical Analysis
For the sample size estimation, we used a previously published study [12] which
demonstrated a 22% lower increase in serum PCSK9 levels when atorvastatin was given
with policosanol vs. atorvastatin and placebo. For a level of significance of 5% and power of
80%, a sample size of 76 patients would be sufficient to detect this level of effect. Allowing
for an estimated dropout rate of 10%, recruitment of 84 patients was needed. The required
sample size was estimated using the Power Analysis and Sample Size software version
11.0.10 (PASS, NCSS statistical software, LLC, Kaysville, UT, USA).
All statistical analyses were performed with SPSS version 20.0 software (Chicago, IL,
USA). All data were assessed for normality. The results are expressed in terms of mean
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values and standard error of mean (SEM) for normally distributed variables, geometric
means and 95% confidence intervals (CI) for variables which were normally distributed
after logarithmic transformation, median, and interquartile range for variables with a
skewed distribution even after logarithmic transformation, and as number (percentage) for
categorical variables. Percentage change was calculated by taking the difference between
the value at 8 or 13 weeks and the basal value, divided by basal value and multiplied by 100.
To compare subjects’ baseline characteristics between the treatment groups, we used an
independent-sample t-test for normally distributed parameters and Mann–Whitney U-test
for parameters that were not normally distributed. Chi-squared-test was used to analyze
the differences in categorical data. ANOVA with repeated measurements was used to
describe the interaction of time and supplementation, effects of investigational supplement
and changes over time (followed by post-hoc comparisons with Bonferroni corrections).
Pearson correlation coefficients were calculated in order to describe the correlation between
the examined parameters. A p value < 0.05 was regarded as statistically significant.
3. Results
3.1. Patient Characteristics
We consecutively screened 177 patients and then enrolled 87 patients, according to the
inclusion/exclusion criteria. Out of 87 patients, 45 (51.7%) and 42 (48.3%) were randomly
assigned to receive placebo or dietary supplement for 13 weeks, respectively. Six patients
dropped out before the endpoint of the study, 5 patients from the dietary supplement
group and 1 patient from the placebo group because of personal reasons not related to the
study and due to gastric distress (Figure 1).
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Baseline characteristics of the patients are shown in Table 1. The mean age of the
patients was 62.6 ± 0.8 years, with males representing 63.2% of the participants. The mean
BMI was 27.6 ± 0.4. More than half of the subjects (52.9%) had a family history of coronary
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heart disease. History of dyslipidemia was present in all patients. Overall, patients
with hypertension, diabetes and current smokers represented 96.6%, 26.4%, and 24.1%
of the study population, respectively. Previous myocardial infarctions and myocardial
revascularization (predominantly by stents) were present in 60% and 62% of patients,
respectively. There were no significant differences in demographic and anthropometric
parameters, smoking status or any of the clinical variables between the groups. There was
also no significant difference in most biochemical parameters between the two groups,
except for TG levels (which were higher in the placebo group, p < 0.05). Concomitant
medications were also equally distributed among the groups. Adherence was 97%, as
defined above.
Table 1. Baseline characteristics of the study population.




(n = 42) p Value
Age (years) 62.6 ± 0.8 61.5 ± 1.2 63.8 ± 1.1 0.165
Sex 0.806
male 55 (63.2) 29 (64.4) 26 (61.9)
female 32 (36.8) 16 (35.6) 16 (38.1)
Body weight (kg) 80.68 ± 1.35 81.05 ± 1.85 80.27 ± 2.00 0.774
Height (cm) 1.71 ± 0.01 1.71 ± 0.01 1.71 ± 0.01 0.773
BMI (kg/m2) 27.6 ± 0.4 27.8 ± 0.5 27.4 ± 0.6 0.604
WC (cm) 97.65 ± 1.08 98.44 ± 1.48 96.79 ± 1.59 0.446
WHR 0.92 ± 0.01 0.93 ± 0.01 0.90 ± 0.01 0.090
Family history of
coronary heart disease 46 (52.9) 26 (57.8) 20 (47.6) 0.343
Smoker 21 (24.1) 11 (24.4) 10 (23.8) 0.945
Diabetes mellitus 23 (26.4) 12 (26.7) 11 (26.2) 0.960
History of hypertension 84 (96.6) 43 (95.6) 41 (97.6) 0.598
Previous myocardial
infarction 52 (59.8) 29 (64.4) 23 (54.8) 0.357
Coronarography 63 (72.4) 33 (73.3) 30 (71.4) 0.843
Stent 54 (62.1) 28 (62.2) 26 (61.9) 0.976
Bypass 4 (4.6) 2 (4.4) 2 (4.8) 0.944
Primary prevention 20 (23.0) 9 (20.0) 11 (26.2) 0.493
CRP (mg/L) † 1.44 (0.90–2.45) 1.59 (0.88–2.45) 1.34 (0.96–2.37) 0.865
Glucose (mmol/L) ‡ 5.64 (5.14–6.19) 5.62 (4.94–6.28) 5.72 (5.19–6.18) 0.494
BP (mm Hg)
Systolic ‡ 130 (120–140) 130 (120–140) 130 (120–140) 0.368
Diastolic ‡ 80 (80–80) 80 (80–80) 80 (80–80) 0.345
Cardioprotective medications
Aspirin/clopidogrel 77 (88.5) 39 (86.7) 38 (90.5) 0.578
Beta-blocker 70 (80.5) 38 (84.4) 32 (76.2) 0.332
CCB 25 (28.7) 12 (26.7) 13 (31.0) 0.659
ACEI/ARB 75 (86.2) 41 (91.1) 34 (81.0) 0.170
Other antihypertensive
drugs 11 (12.6) 4 (8.9) 7 (16.7) 0.275
Diuretics 41 (47.1) 23 (51.1) 18 (42.9) 0.441
Antianginal drugs 40 (46.0) 20 (44.4) 20 (47.6) 0.767
Atorvastatin 87 (100.0) 45 (100.0) 42 (100.0)
TC (mmol/L) 4.60 ± 0.12 4.61 ± 0.16 4.60 ± 0.18 0.944
TG (mmol/L) † 1.33 (1.20–1.47) 1.49 (1.28–1.72) 1.16 (1.03–1.32) 0.012
HDL-C (mmol/L) 1.36 ± 0.04 1.30 ± 0.05 1.45 ± 0.06 0.053
LDL-C (mmol/L) 2.66 ± 0.10 2.70 ± 0.15 2.61 ± 0.16 0.685
Data are shown as mean ± SEM or as a number (percentage) unless otherwise specified († geometric mean values (95th CI), ‡ median
(interquartile range)); BMI: Body mass index; WC: Waist circumference; WHR: Waist-to-hip ratio; CRP: C-reactive protein; BP: Blood
pressure; CCB: Calcium channel blocker; ACEI: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin receptor blocker; TC: Total
cholesterol; TG: Triglycerides; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol.
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3.2. Effects on PCSK9 and Lipids Parameters
Table 2 shows serum PSCK9 levels and lipid parameters at baseline, after 8 and
13 weeks. PCSK9 levels remained constant during the study period in both groups. The
TC and ApoA1 levels did not significantly change over the study period in both groups.
There was a statistically significant decrease in LDL-C levels in the placebo group after
8 weeks compared with baseline (interaction effect of supplementation and time, p = 0.023),
but the effect disappeared after 13 weeks. Baseline serum levels of TG were significantly
higher in the placebo group than in the dietary supplement group (p = 0.012). The serum
levels of TG significantly increased after 8 weeks compared with baseline in the dietary
supplement group (main effect of time, p = 0.007), but the effect disappeared after 13 weeks.
No changes from baseline HDL-C values were observed in patients treated with dietary
supplement over the 13-week period, whereas an increase in HDL-C values was observed
in the placebo group (p < 0.001, Bonferroni post-hoc test). The serum level of ApoB100
increased significantly (but clinically not relevant) after 8 weeks compared with baseline in
the dietary supplement group, but the effect disappeared after 13 weeks (main effect of
time, p = 0.025).
Table 2. Serum PSCK9 and lipid parameters at baseline, after 8 weeks and 13 weeks of supplementation.
Variable Placebo (n = 44) Dietary Supplement (n = 37) ANOVA (p)
Baseline 8 Weeks 13 Weeks Baseline 8 Weeks 13 Weeks T S T × S
PCSK9
(ng/mL) 245.24 ± 19.03 264.91 ± 14.92 264.54 ± 20.46 233.96 ± 20.75 236.41 ± 16.27 237.80 ± 22.31 0.698 0.218 0.807
TC (mmol/L) 4.61 ± 0.16 4.53 ± 0.16 4.69 ± 0.16 4.60 ± 0.18 4.85 ± 0.17 4.84 ± 0.18 0.192 0.479 0.165
TG (mmol/L)
† 1.49 (1.28–1.72) 1.64 (1.43–1.87) 1.55 (1.34–1.79) 1.16 (1.03–1.32) 1.35 (1.17–1.56) * 1.20 (1.03–1.41) 0.007 0.012 0.731
HDL-C
(mmol/L) 1.30 ± 0.05 1.37 ± 0.05 1.50 ± 0.06 **
,# 1.45 ± 0.06 1.40 ± 0.06 1.47 ± 0.06 0.007 0.416 0.041
LDL-C
(mmol/L) 2.70 ± 0.15 2.36 ± 0.14 * 2.53 ± 0.16 2.61 ± 0.16 2.81 ± 0.16 2.73 ± 0.17 0.761 0.341 0.023
ApoA1 (g/L) 1.41 ± 0.04 1.44 ± 0.04 1.42 ± 0.04 1.48 ± 0.04 1.46 ± 0.04 1.45 ± 0.04 0.638 0.389 0.309
ApoB100 (g/L) 1.87 ± 0.07 1.86 ± 0.08 1.97 ± 0.08 1.84 ± 0.08 2.02 ± 0.09 * 1.98 ± 0.09 0.025 0.632 0.084
Values are expressed as mean ± SEM or † geometric mean values (95th confidence interval), as appropriate. Mixed model ANOVA
produced p values for effects of: T-time, S-supplementation, T × S-time and supplementation interaction effect; PCSK9: Proprotein
convertase subtilisin/kexin type 9; TC: Total cholesterol; TG: Triglycerides; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-
density lipoprotein cholesterol; ApoA1: Apolipoprotein A1; ApoB100: Apolipoprotein B100. * p < 0.05 versus baseline; ** p < 0.01 versus
baseline; # p < 0.05 versus 8 weeks (post-hoc pairwise comparisons with Bonferroni correction).
A Pearson correlation analysis did not show any significant correlation between PCSK9
levels and age, BMI, TC, LDL-C, HDL-C, ApoA1, ApoB100, and TG either at baseline or
after 13 weeks of intervention regardless of whether patients were using atorvastatin alone
or in combination with dietary supplement.
We observed a significant positive correlation between the percentage change in
PCSK9 levels and those in LDL-C levels as soon as after 8 weeks (r = 0.383, p = 0.019), and
it remained at week 13, i.e., from baseline to endpoint (r = 0.409, p = 0.012) (Figure 2A,C) in
the dietary supplement group. Such a correlation was not detected in the placebo group
(week 8—r = 0.078, p = 0.615; week 13—r = −0.103, p = 0.508) (Figure 2B,D). Therefore,
supplemented subjects that had the greatest decrease in PCSK9 levels tended to have the
largest decrease in serum LDL-C levels.
Significant negative correlation between the percentage change in PCSK9 levels and
those in HDL-C levels was found after 8 weeks (r = −0.369, p = 0.025), but this correlation
was lost at week 13, i.e., from baseline to endpoint (r = −0.276, p = 0.098) (Supplementary
Figure S1A,C) in patients with combination of statin and the dietary supplement. Such a
correlation was not detected in the placebo group (week 8—r = −0.105, p = 0.498; week
13—r = −0.063, p = 0.686) (Supplementary Figure S1B,D). Therefore, supplemented subjects
that had the greatest decrease in PCSK9 levels tended to have the largest increase in serum
HDL-C levels after 8 weeks but this correlation disappeared after 13 weeks
Nutrients 2021, 13, 903 7 of 12
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3.3. Safety 
AST levels significantly decreased in both groups, with a more pronounced decrease 
in the dietary supplement group (main effect of time, p < 0.001). In addition, supplemen-
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there was no single report indicating that elevated PCSK9 might be independent health 
prognostic factor regardless of LDL-C level. The two groups were well matched in terms 
of all variables, except TG levels. Almost 80% of the patients had a history of ischemic 
heart disease and were eligible for secondary prevention of cardiovascular events. The 
study population (n = 87) was large enough to address the objectives of the study. Our 
results showed no adverse effects in the study population regarding ALT and AST levels 
(in fact, a decrease of these enzymes was observed) as well as on CK levels.  
The main findings of our study, outlined according to originality and importance are 
as follows.  
First, the most striking and interesting result is the presence of a positive correlation 
between percentage changes in PCSK9 and those in LDL-C levels as early as after 8 weeks, 
remaining at 13 weeks in the supplemented group (week 8—r = 0.383, p = 0.019; week 13—
r = 0.409, p = 0.012). Therefore, supplemented subjects that had the greatest decrease in 
PCSK9 levels tended to have the largest decrease in serum LDL-C, which is in contrast to 
all statin studies [10,11,26]. More specifically, several previous studies have found that the 
greatest increase of PCSK9 levels is seen in patients with the greatest response to statin 
therapy [11,27]. There is a significant negative correlation between the percentage change 
in PCSK9 levels and those in HDL-C levels was found after 8 weeks (r = −0.369, p = 0.025), 
but this correlation was lost at week 13 in patients with combination of statin and the 
dietary supplement. Actually, dietary supplement reestablished the disrupted physio-
logic relationship between LDL-C and PCSK9 levels, induced by chronic statin use. To the 
Figure 3. Serum PCSK9 levels at baseline and after 13 weeks of supplementation in patients (A) with favorable changes
of LDL-C and HDL-C and (B) with non-favorable changes of LDL-C and HDL-C. Columns represent mean group
values ± SEM. Abbreviations: HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol;
PCSK9, proprotein convertase subtilisin kexin type 9.
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PCSK9 levels during the study period in subjects with non-favorable lipid profile
changes are shown in Figure 3B. No significant changes in PCSK9 levels were observed in
the dietary supplement group nor placebo group.
3.3. Safety
AST levels significantly decreased in both groups, with a more pronounced decrease in
the dietary supplement group (main effect of time, p < 0.001). In addition, supplementation
with dietary supplement significantly decreased ALT levels by the end of the study period
(interaction effect of supplementation and time, p < 0.05). CK values did not significantly
change over the study period in both groups (Supplementary Table S1).
4. Discussion
The present study was conceived and undertaken to investigate the potential additive
or synergistic effects of dietary supplement on serum PCSK9 levels and lipid profile
parameters when used with background long term atorvastatin therapy at the time when
there was no single report indicating that elevated PCSK9 might be independent health
prognostic factor regardless of LDL-C level. The two groups were well matched in terms of
all variables, except TG levels. Almost 80% of the patients had a history of ischemic heart
disease and were eligible for secondary prevention of cardiovascular events. The study
population (n = 87) was large enough to address the objectives of the study. Our results
showed no adverse effects in the study population regarding ALT and AST levels (in fact, a
decrease of these enzymes was observed) as well as on CK levels.
The main findings of our study, outlined according to originality and importance are
as follows.
First, the most striking and interesting result is the presence of a positive correlation
between percentage changes in PCSK9 and those in LDL-C levels as early as after 8 weeks,
remaining at 13 weeks in the supplemented group (week 8—r = 0.383, p = 0.019; week 13—
r = 0.409, p = 0.012). Therefore, supplemented subjects that had the greatest decrease in
PCSK9 levels tended to have the largest decrease in serum LDL-C, which is in contrast to
all statin studies [10,11,26]. More specifically, several previous studies have found that the
greatest increase of PCSK9 levels is seen in patients with the greatest response to statin
therapy [11,27]. There is a significant negative correlation between the percentage change
in PCSK9 levels and those in HDL-C levels was found after 8 weeks (r = −0.369, p = 0.025),
but this correlation was lost at week 13 in patients with combination of statin and the
dietary supplement. Actually, dietary supplement reestablished the disrupted physiologic
relationship between LDL-C and PCSK9 levels, induced by chronic statin use. To the best of
our knowledge, this is the first study which has demonstrated described effect on humans.
Second, in both patient groups, the absolute levels of PCSK9 did not change signifi-
cantly over the study period. In the study by Guo et al., 36 patients, who had no history of
statin use within the previous month, were assigned to receive either atorvastatin (n = 17;
5 patients lost of follow up) or atorvastatin plus policosanol (n = 19; 5 patients lost of
follow up). The study showed that during 8 weeks of atorvastatin monotherapy serum
PCSK9 levels significantly increased (by 39.4%) in comparison to pretreatment values
(p = 0.002). However, in the group which received policosanol with atorvastatin PCSK9
levels increased by 17.4%, without statistical significance when compared to basal values
(p = 0.184) [12]. This finding indicates that policosanol might attenuate statin-induced
increases in serum PCSK9 levels in statin-naive patients. In healthy volunteers (n = 7),
treated with policosanol for 12 weeks, a decrease of PCSK9 levels was observed, but did
not reach statistical significance (p = 0.069) [12].
In a post-hoc explanatory analysis, when the patients were classified as having favor-
able changes of lipid parameters (LDL-C decrease and HDL-C increase) [28], a statistical
trend towards PCSK9 decrease in the supplemented group as well as PCSK9 increase in
the placebo group after 13 weeks of intervention, has been found. Difference in PCSK9
levels, from baseline to 8 and 13 weeks, between the supplementation and placebo group
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showed a strong trend of PCSK9 decrease only in patients with favorable lipids changes in
the supplemented group (p = 0.077). It might be that these patients had physiological regu-
latory changes of PCSK9 and LDL-C, which restored the positive correlation between them.
Described trend was absent in 50% of patients in the placebo group who had favorable
changes in the lipid profile (Figure 3A).
Certain genetic differences could explain different response in patients supplemented
with Octacosanol/vitamin K2 regarding PSCK9 and LDL-C levels. Concomitant fall in
PCSK9 and LDL-C after the supplementation could be determined by PCSK9 polymor-
phism which enabled octasosanol/vitamin K2 to restore positive correlation between them.
In the study investigating the effect of multicomponent dietary supplement (policosanol,
fermented rice with red yeast, berberine, coenzyme Q10, folic acid, and astaxanthin) in
people with moderate hypercholesterolemia, a large interindividual variability in the LDL-
C response to supplementation was observed [29]. It was shown that LDLR and PCSK9
polymorphisms were associated with response to supplementation.
There was a statistically significant decrease in LDL-C levels in the placebo group after
8 weeks (but not after 13 weeks) compared with baseline. These reductions were around
10% and therefore of limited clinical relevance. Of note is the fact that in other studies,
where patients were treated with statins and/or PCSK9 inhibitors, some fluctuations of
LDL-C levels over time were observed [4,30]. It is not clear if these fluctuations reflected
some dietary changes or were due to some other factors.
Third, dietary supplement, as expected, did not offer additional lipoprotein benefits
when added to background statin therapy (Table 2), similarly to previous studies which
examined the combined use of policosanol and statins [2,4]. It is possible that we did not
detect a significant effect of dietary supplement on LDL-C in our patients, because they
were already decreased by statin use. This is supported by the evidence which suggests
that baseline LDL-C levels could determine overall LDL-C reduction [31,32].
Although dietary supplement in our study did not show any lipid lowering benefits,
its combination with atorvastatin may be useful in an attempt to avoid potential adverse
effects that are associated with statin-induced increases of PCSK9 level. The hypothesis
that the prognosis of patients will be better with lower LDL-C levels, and while keeping
PCSK9 levels under control (which was found in our study for some patients receiving
dietary supplement), remains to be confirmed in larger studies [20,21].
Interestingly, in one study of the general population PCSK9 levels demonstrated a
week correlation with LDL-C (r2 = 0.06, explaining less than 6% of the variation in LDL-
C) [33]. However, despite the low aforementioned coefficient of determination (0.06) the
PCSK9 inhibitors have been proven to be very effective in decreasing LDL-C (up to 60%
from basal values). Having in mind such exemplary discordance, one should view the
significance of our results where PCSK9 levels explained LDL-C by 17% (r = 0.409) in
patients receiving dietary supplement. One possible explanation may be that that quality,
not the quantity of PCSK9, is of higher importance.
The strengths of the present study were as follows: The study design (prospective,
randomized, double-blind, placebo-controlled), a high level of compliance and only six
participant withdrawals. PCSK9 levels were measured using a validated methodology and
our values are in line with a recently reported study [21]. LDL-C levels were measured,
not calculated as in many studies. The investigated supplement possessed a good safety
profile and tolerability.
Our study had certain limitations. It was a single-center study and we enrolled only
patients who had been taking atorvastatin for 4 months, without a group of statin-naive
patients as we took the findings by Guo et al. as granted [12]. It is possible that the
simultaneous start of policosanol and statin would have been more effective at regulating
PCSK9 levels than adding policosanol to chronic statin therapy. Also, just one dose of
Octacosanol was used. Additionally, we did not measure either the level of atorvastatin,
or the level of Octacosanol/Vitamin K2 in the serum, but the lipid profiles of our patients
in the time course were suggestive of excellent compliance with statin use. The fact that
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disrupted association between LDL-C and PCSK9 levels was reestablished only in the
supplemented group in both time points, indicates that patients were compliant with
the therapy. We used this particular supplement because it was available as an over-the-
counter product, therefore production and/or regulatory restrictions were not present. We
could not exactly distinguish the effect of Octacosanol vs. vitamin K2, but all the available
data indicate that low-dose vitamin K2 (45 µg) does not have any lipid regulating effects.
However, vitamin K2 has a potential health benefit for cardiovascular disease prevention,
related to protection against vascular calcification [34,35].
A larger sample and a longer period of supplementation could provide more spe-
cific results regarding Octacosanol effects as well as its underlying mechanism in PSCK9
regulation. It could also enable a generalization of the study. Since, this was an investigator-
initiated study with zero funding, it was not possible to include a larger number of patients.
Last but not least, the clinical endpoints of the reduction of PCSK9 levels induced
by dietary supplement will need to be documented. This is of particular importance,
considering that PCSK9 inhibitors are highly effective at decreasing LDL-C, but have a
very limited effect in decreasing clinical events, especially mortality.
5. Conclusions
This is the first study to show that dietary supplement can restore the physiologic
positive correlation between PCSK9 and LDL-C levels, disrupted by statin therapy. Treat-
ment with statins and/or PCSK9 inhibitors provokes an increase of PCSK9 and a negative
correlation between PCSK9 and LDL-C levels. Our finding could be clinically relevant,
considering that spontaneous and/or drug-induced elevations of PCSK9 levels may be an
independent health risk factor.
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